Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

First-in-human trial for GB-0669 in patients with SARS-CoV-2

Next Previous
Search
Trial Profile

First-in-human trial for GB-0669 in patients with SARS-CoV-2

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GB 0669 (Primary)
  • Indications SARS-CoV-2 acute respiratory disease
  • Focus Adverse reactions; First in man

    • Most Recent Events

    • 09 Jan 2025 According to a Generate Biomedicines media release, results from this study were presented at IDWeek 2024.
    • 04 Jan 2024 According to a Generate Biomedicines Media Release, safety has been shown for the first four of five planned cohorts, including the putative recommended dose; analysis of key biomarkers is ongoing.
    • 04 Jan 2024 According to a Generate Biomedicines Media Release, company will present updates from GB-0669 program, at the 42nd Annual J.P. Morgan Healthcare Conference, which will be occurring from January 8-11 in San Francisco. The presentation will take place on Jan 10 from 10:00-10:25am PST at the Golden Gate (32nd Floor) of The Westin St. Francis.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top